Ann: Phase II Clinical Trial - First Patient In, page-7

FTT sure is friendless at the moment. Only around 5 million shares have traded altogether in last 6 weeks, or $300,000 worth at today's price.

Not even Bioshares picking FTT as one of their 6 top biotechs for 2017 managed to attract any buying interest.

This is a bit surprising because Bioshares seems to be remarkably clever at picking the top 6 biotechs for each year:

I was stunned when I read their track record:

Bioshares Top 6 Stock Pick Track Record

2016 83.7%
2015 53.1%
2014 40.8%
2013 62.2%
2012 36.2%

oh well...